SCHEMBL25280258

SCHEMBL25280258

CNC(=O)c1c(N)cc(Br)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 5/20 0.41
CREBBP Q92793 1/20 0.39
CFTR P13569 1/20 0.37
SCN10A Q9Y5Y9 3/20 0.35
HPGD P15428 3/20 0.34
ALDH1A1 P00352 1/20 0.34
SCN9A Q15858 2/20 0.34
SCN2A Q99250 2/20 0.34
SCN3A Q9NY46 2/20 0.34
DOT1L Q8TEK3 1/20 0.34
SCN1A P35498 1/20 0.34
KCNH2 Q12809 1/20 0.34
SCN5A Q14524 1/20 0.34
KMT2A Q03164 1/20 0.33
ALOX15 P16050 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
MAPK1 P28482 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4214376 0.82 SCN10A (0.44) WDR5SCN10AHPGDALDH1A1SCN9A
SCHEMBL25282174 0.82 PRKCZ (0.44) HPGDALDH1A1KMT2AALOX15
SCHEMBL25236900 0.79 WDR5 (0.45) WDR5CREBBPHPGDALDH1A1DOT1L
SCHEMBL31057270 0.79 GAA (0.45) CFTRHPGDALDH1A1ALOX15
SCHEMBL7781021 0.78 KDM4E (0.41) WDR5HPGDALDH1A1MAPK1
SCHEMBL8048802 0.78 NMT1 (0.35)
SCHEMBL31057404 0.78 KDM4E (0.41) WDR5HPGDALDH1A1MAPK1
SCHEMBL25235947 0.72 WDR5 (0.38) WDR5CREBBPCFTRSCN10AHPGD
SCHEMBL7457606 0.71 JAK1 (0.58) HPGDALDH1A1DOT1LKMT2A
SCHEMBL11658079 0.71 SCN10A (0.41) CFTRSCN10AHPGDALDH1A1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163022-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4452963-A1 PARP1 INHIBITORS Synnovation Therapeutics, Inc. (US) 2024-10-30 EP disclosed
CN-118696036-A PARP1 inhibitors 突触活化疗法股份有限公司 2024-09-24 CN disclosed
WO-2023122140-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-06-29 WO disclosed
WO-2023122140-A1 PARP1 INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163022-A1 PARP1 INHIBITORS PARP1, PARP11, PARP12 WDR5 1396/4885CREBBP 229/4885CFTR 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.